Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome

Crit Care. 2020 Sep 24;24(1):574. doi: 10.1186/s13054-020-03293-8.
No abstract available

Keywords: COVID-19; Critical care; Immunomodulatory agents; Pulmonary edema; Respiratory distress syndrome, adult; Therapies, investigational.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Betacoronavirus
  • COVID-19
  • Comorbidity
  • Coronavirus Infections / therapy*
  • Critical Illness / therapy*
  • Female
  • Fibrin Fibrinogen Degradation Products / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Pandemics
  • Peptide Fragments / therapeutic use*
  • Pneumonia, Viral / therapy*
  • Respiratory Distress Syndrome / therapy*
  • Respiratory Distress Syndrome / virology
  • SARS-CoV-2
  • Salvage Therapy*

Substances

  • Fibrin Fibrinogen Degradation Products
  • Peptide Fragments
  • fibrinogen Bbeta (15-42)